First Tracks Biotherapeutics Announces $200 Million Private Placement

First Tracks Biotherapeutics agreed to sell 6,106,870 shares of common stock at $32.75 per share in a private placement. Expected gross proceeds total approximately $200 million before placement agent fees and other expenses. Closing is expected on October 19, 2026, subject to customary closing conditions. Proceeds will fund general corporate purposes, including clinical development of ANB033, a CD122 antagonist. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. First Tracks Biotherapeutics Inc. published the original content used to generate this news brief via (Ref. ID: 202610150800PRIMZONEFULLFEED9846315) on October 15, 2026, and is solely responsible for the information contained therein. (C)